Assenagon Asset Management S.A. Cardiff Oncology, Inc. Transaction History
Assenagon Asset Management S.A.
- $39.3 Billion
- Q2 2024
A detailed history of Assenagon Asset Management S.A. transactions in Cardiff Oncology, Inc. stock. As of the latest transaction made, Assenagon Asset Management S.A. holds 1,215,922 shares of CRDF stock, worth $2.69 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
1,215,922
Previous 252,982
380.64%
Holding current value
$2.69 Million
Previous $1.35 Million
99.93%
% of portfolio
0.01%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding CRDF
# of Institutions
98Shares Held
12.8MCall Options Held
823KPut Options Held
78K-
Black Rock Inc. New York, NY2.63MShares$5.81 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.14MShares$4.72 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA911KShares$2.01 Million0.0% of portfolio
-
State Street Corp Boston, MA805KShares$1.78 Million0.0% of portfolio
-
Mai Capital Management659KShares$1.46 Million0.01% of portfolio
About Cardiff Oncology, Inc.
- Ticker CRDF
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,334,900
- Market Cap $95.8M
- Description
- Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...